BioCentury | Mar 21, 2016
Clinical News

Nanocort: Phase IIa data

...and gastritis. Data were presented at the European Crohn’s and Colitis Organization meeting in Amsterdam. Enceladus Pharmaceuticals B.V....
BioCentury | Apr 18, 2011
Company News

Enceladus, Galapagos deal

...Galapagos said on a conference call that it sent notice to Enceladus that it is terminating...
...a decision on the future of the Phase II trial (see BioCentury, April 21, 2008). Enceladus Pharmaceuticals B.V....
BioCentury | Apr 16, 2011
Clinical News

Galapagos falls after stopping RA trial

...Galapagos did not comment on the status of the partnership. Galapagos also said it notified Enceladus Pharmaceuticals B.V....
BioCentury | Nov 23, 2009
Clinical News

Nanocort: Phase II started

...The company licensed exclusive, worldwide rights to develop and market Nanocort from Enceladus last year. Enceladus Pharmaceuticals B.V....
BioCentury | Nov 3, 2008
Clinical News

Nanocort: Phase I/II data

...meeting in San Francisco. Galapagos has exclusive, worldwide rights to develop and market Nanocort from Enceladus Pharmaceuticals B.V....
BioCentury | Apr 21, 2008
Company News

Enceladus, Galapagos deal

...Ph I/II trials in 1H09 to treat multiple sclerosis (MS) and inflammatory bowel disease (IBD). Enceladus...
...an undisclosed upfront payment and is eligible for a minority share of future Nanocort revenue. Enceladus Pharmaceuticals B.V....
BioCentury | Jul 2, 2007
Company News

Enceladus management update

Enceladus Pharmaceuticals B.V. , Amsterdam, the Netherlands Business: Autoimmune, Cancer Hired: Cees Wortel as acting CMO while remaining CEO of Clinquest Group B.V. WIR Staff autoimmune cancer...
Items per page:
1 - 7 of 7
BioCentury | Mar 21, 2016
Clinical News

Nanocort: Phase IIa data

...and gastritis. Data were presented at the European Crohn’s and Colitis Organization meeting in Amsterdam. Enceladus Pharmaceuticals B.V....
BioCentury | Apr 18, 2011
Company News

Enceladus, Galapagos deal

...Galapagos said on a conference call that it sent notice to Enceladus that it is terminating...
...a decision on the future of the Phase II trial (see BioCentury, April 21, 2008). Enceladus Pharmaceuticals B.V....
BioCentury | Apr 16, 2011
Clinical News

Galapagos falls after stopping RA trial

...Galapagos did not comment on the status of the partnership. Galapagos also said it notified Enceladus Pharmaceuticals B.V....
BioCentury | Nov 23, 2009
Clinical News

Nanocort: Phase II started

...The company licensed exclusive, worldwide rights to develop and market Nanocort from Enceladus last year. Enceladus Pharmaceuticals B.V....
BioCentury | Nov 3, 2008
Clinical News

Nanocort: Phase I/II data

...meeting in San Francisco. Galapagos has exclusive, worldwide rights to develop and market Nanocort from Enceladus Pharmaceuticals B.V....
BioCentury | Apr 21, 2008
Company News

Enceladus, Galapagos deal

...Ph I/II trials in 1H09 to treat multiple sclerosis (MS) and inflammatory bowel disease (IBD). Enceladus...
...an undisclosed upfront payment and is eligible for a minority share of future Nanocort revenue. Enceladus Pharmaceuticals B.V....
BioCentury | Jul 2, 2007
Company News

Enceladus management update

Enceladus Pharmaceuticals B.V. , Amsterdam, the Netherlands Business: Autoimmune, Cancer Hired: Cees Wortel as acting CMO while remaining CEO of Clinquest Group B.V. WIR Staff autoimmune cancer...
Items per page:
1 - 7 of 7